These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

744 related items for PubMed ID: 29508719

  • 1. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
    Nettis E, Cegolon L, Di Leo E, Canonica WG, Detoraki A, Italian OCUReL Study Group.
    Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
    [Abstract] [Full Text] [Related]

  • 2. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F, Ferrier Le Bouedec MC, Bouillet L, Reguiai Z, Barbaud A, Cambazard F, Milpied B, Pelvet B, Kasujee I, Gharbi H, Lacour JP.
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [Abstract] [Full Text] [Related]

  • 3. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Canvin J, Maurer M.
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [Abstract] [Full Text] [Related]

  • 4. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
    Nettis E, Cegolon L, Di Leo E, Lodi Rizzini F, Detoraki A, Canonica GW, Italian OCUReL study group.
    Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
    Kulthanan K, Tuchinda P, Chularojanamontri L, Likitwattananurak C, Ungaksornpairote C.
    J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
    [Abstract] [Full Text] [Related]

  • 9. The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months' Evolution and Prior Immunosuppressive Treatment.
    Cubiró X, Spertino J, Rozas-Muñoz E, Serra-Baldrich E, Puig L.
    Actas Dermosifiliogr (Engl Ed); 2019 May; 110(4):289-296. PubMed ID: 30360885
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
    Kitsioulis NA, Xepapadaki P, Roussaki-Schulze AV, Papadopoulos N, Zafiriou E.
    Int Arch Allergy Immunol; 2017 May; 172(3):161-166. PubMed ID: 28380487
    [Abstract] [Full Text] [Related]

  • 11. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C, Toubi E, Maurer M, Triggiani M, Ballmer-Weber B, Marsland A, Ferrer M, Knulst A, Giménez-Arnau A.
    Eur J Dermatol; 2017 Feb 01; 27(1):10-19. PubMed ID: 27882879
    [Abstract] [Full Text] [Related]

  • 12. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M, Gameiro A, Pinho A, Gonçalo M.
    Clin Exp Dermatol; 2017 Oct 01; 42(7):735-742. PubMed ID: 28649751
    [Abstract] [Full Text] [Related]

  • 13. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
    Altrichter S, Staubach P, Pasha M, Singh B, Chang AT, Bernstein JA, Rasmussen HS, Siebenhaar F, Maurer M.
    J Allergy Clin Immunol; 2022 May 01; 149(5):1683-1690.e7. PubMed ID: 34954198
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
    Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, Rosén K, Omachi TA, Khalil S, Zazzali JL.
    J Allergy Clin Immunol; 2016 Feb 01; 137(2):474-81. PubMed ID: 26483177
    [Abstract] [Full Text] [Related]

  • 17. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM.
    Expert Opin Biol Ther; 2017 Mar 01; 17(3):375-385. PubMed ID: 28125304
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M, Costa C, Gimenez Arnau A, Guillet G, Labrador-Horrillo M, Lapeere H, Meshkova R, Savic S, Chapman-Rothe N.
    Clin Exp Allergy; 2020 Oct 01; 50(10):1166-1175. PubMed ID: 32735720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.